Gore’s TAG Thoracic Endograft Is First To Go Before FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
A favorable recommendation by FDA's Circulatory System Devices Panel would place W.L. Gore one step closer to becoming the first firm with U.S. market approval for a thoracic aortic aneurysm endograft
You may also be interested in...
Panel Critiques TAG Graft Study Size, But Deems Approval “Common Sense”
The appeal of WL Gore's TAG thoractic endograft as a less-invasive alternative to open-heart surgery swayed FDA panelists to recommend device approval Jan. 13
Panel Critiques TAG Graft Study Size, But Deems Approval “Common Sense”
The appeal of WL Gore's TAG thoractic endograft as a less-invasive alternative to open-heart surgery swayed FDA panelists to recommend device approval Jan. 13
FDA Relaxes AAA Panel Meeting Criteria; Thoracic Endograft Approvals Lag
Abdominal aortic aneurysm endograft applications will no longer require advisory panel review, unless new issues arise in the course of FDA's premarket evaluation